STOCK TITAN
  1. Home
  2. SEC Filings
  3. SNSE
  4. [Form 4] Sensei Biotherapeutics, Inc. Insider Trading Activity

[Form 4] Sensei Biotherapeutics, Inc. Insider Trading Activity

Sensei Biotherapeutics, Inc. reported a series of open-market trades in its Common Stock by entities associated with Millennium Management LLC over March 26–30, 2026.

Filing Impact
(Very High)
Filing Sentiment

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment worksHow the balance works

Form Type
4

Rhea-AI Filing Summary

Sensei Biotherapeutics, Inc. reported a series of open-market trades in its Common Stock by entities associated with Millennium Management LLC over March 26–30, 2026. The trades were executed by ICS Opportunities II LLC or other trading entities subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander.

Across these dates, the entities reported purchases of 30,585 shares and sales of 3,250 shares, resulting in a net purchase of 27,335 shares of Sensei Biotherapeutics Common Stock. Following the transactions on March 30, 2026, Millennium Management LLC is reported as beneficially owning 145,678 shares, with each reporting person disclaiming beneficial ownership beyond any pecuniary interest.

Insider MILLENNIUM MANAGEMENT LLC, ICS OPPORTUNITIES II LLC, MILLENNIUM GROUP MANAGEMENT LLC, ENGLANDER ISRAEL A
Role 10% Owner | 10% Owner | 10% Owner | 10% Owner
Bought 30,585 shs ($818K)
Sold 3,250 shs ($89K)
Type Security Shares Price Value
Purchase Common Stock 2,992 $25.0784 $75K
Purchase Common Stock 4,995 $25.99 $130K
Purchase Common Stock 1,176 $26.70 $31K
Purchase Common Stock 370 $27.68 $10K
Sale Common Stock 518 $25.8501 $13K
Sale Common Stock 370 $27.68 $10K
Purchase Common Stock 10,643 $26.2933 $280K
Purchase Common Stock 4,384 $27.2826 $120K
Purchase Common Stock 294 $28.1301 $8K
Sale Common Stock 469 $26.7652 $13K
Sale Common Stock 36 $27.369 $985.28
Purchase Common Stock 778 $27.2267 $21K
Purchase Common Stock 1,327 $27.9467 $37K
Purchase Common Stock 2,601 $28.8539 $75K
Purchase Common Stock 1,025 $29.9788 $31K
Sale Common Stock 583 $26.8797 $16K
Sale Common Stock 1,274 $28.6882 $37K
Holdings After Transaction: Common Stock — 145,678 shares (Indirect, See footnote)
Footnotes (19)
  1. F1. Represents volume-weighted average price ("VWAP") of purchases of 778 shares of common stock ("Common Stock"), par value $0.0001 per share, of Sensei Biotherapeutics, Inc. (the "Company") on March 26, 2026 at prices ranging from $26.66 to $27.62. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting persons will provide full information regarding the number of shares purchased or sold by the reporting person at each separate price within each range represented by a VWAP disclosed herein.
  2. F2. In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2.
  3. F3. The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any.
  4. F4. Represents VWAP of purchases of 1,327 shares of the Company's Common Stock on March 26, 2026 at prices ranging from $27.70 to $28.4163.
  5. F5. Represents VWAP of purchases of 2,601 shares of the Company's Common Stock on March 26, 2026 at prices ranging from $28.7072 to $29.51.
  6. F6. Represents VWAP of purchases of 1,025 shares of the Company's Common Stock on March 26, 2026 at prices ranging from $29.79 to $30.105.
  7. F7. Represents VWAP of sales of 583 shares of the Company's Common Stock on March 26, 2026 at prices ranging from $26.68 to $27.4650.
  8. F8. Represents VWAP of sales of 1,274 shares of the Company's Common Stock on March 26, 2026 at prices ranging from $28.07 to $28.7651.
  9. F9. Represents VWAP of purchases of 10,643 shares of the Company's Common Stock on March 27, 2026 at prices ranging from $25.9197 to $26.88.
  10. F10. Represents VWAP of purchases of 4,384 shares of the Company's Common Stock on March 27, 2026 at prices ranging from $26.9750 to $27.68.
  11. F11. Represents VWAP of purchases of 294 shares of the Company's Common Stock on March 27, 2026 at prices ranging from $28.10 to $28.60.
  12. F12. Represents VWAP of sales of 469 shares of the Company's Common Stock on March 27, 2026 at prices ranging from $26.21 to $26.95.
  13. F13. Represents VWAP of sales of 36 shares of the Company's Common Stock on March 27, 2026 at prices ranging from $27.2322 to $27.68.
  14. F14. Represents VWAP of purchases of 2,992 shares of the Company's Common Stock on March 30, 2026 at prices ranging from $24.495 to $25.1856.
  15. F15. Represents VWAP of purchases of 4,995 shares of the Company's Common Stock on March 30, 2026 at prices ranging from $25.50 to $26.48.
  16. F16. Represents VWAP of purchases of 1,176 shares of the Company's Common Stock on March 30, 2026 at prices ranging from $26.50 to $26.90.
  17. F17. Represents purchases of 370 shares of the Company's Common Stock on March 30, 2026 at $27.68 per share.
  18. F18. Represents VWAP of sales of 518 shares of the Company's Common Stock on March 30, 2026 at prices ranging from $25.13 to $26.0734.
  19. F19. Represents sales of 370 shares of the Company's Common Stock on March 30, 2026 at $27.68 per share.
Shares purchased 30,585 shares Open-market purchases of Common Stock, March 26–30, 2026
Shares sold 3,250 shares Open-market sales of Common Stock, March 26–30, 2026
Net shares bought 27,335 shares Net of purchases and sales in transaction summary
Shares held after trades 145,678 shares Beneficially owned by Millennium Management LLC after March 30, 2026 trades
VWAP range example $25.9197–$26.88 VWAP range for 10,643-share purchase block on March 27, 2026
Single-price trade $27.68 per share 370-share purchase and 370-share sale on March 30, 2026
volume-weighted average price ("VWAP") financial
"Represents volume-weighted average price ("VWAP") of purchases of 778 shares of common stock"
Volume-weighted average price (VWAP) is the average price a stock has traded at over a day, where each price is weighted by how many shares changed hands at that price — like calculating the average cost per item but giving larger purchases more influence. Investors and traders use VWAP as a benchmark to judge whether trades were executed at favorable prices and to guide large orders so they don’t move the market too much.
beneficially owned financial
"the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
voting control and investment discretion financial
"subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC"
pecuniary interest financial
"disclaims beneficial ownership of the shares ... except to the extent of such reporting person's pecuniary interest therein"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many Sensei Biotherapeutics (SNSE) shares did Millennium entities buy and sell?
The reporting entities purchased 30,585 shares and sold 3,250 shares of Sensei Biotherapeutics Common Stock. This activity produced a net purchase of 27,335 shares over the reported period, reflecting more buying than selling in these transactions.

What is the reported Sensei Biotherapeutics (SNSE) position after these trades?
After the transactions on March 30, 2026, Millennium Management LLC is reported as beneficially owning 145,678 shares of Sensei Biotherapeutics Common Stock. This figure reflects holdings at the conclusion of the reported trades on that date, as stated in the filing footnotes.

Who actually executed the SNSE trades disclosed by Millennium in this Form 4?
The trades in Sensei Biotherapeutics Common Stock were made by ICS Opportunities II LLC or other trading entities. These entities are subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander, according to the footnotes.

Do the Millennium reporting persons fully own all the SNSE shares reported?
Each reporting person disclaims beneficial ownership of the Sensei Biotherapeutics shares except to the extent of their pecuniary interest. This means they report the holdings but state they may not economically benefit from all shares in the same way.

What price ranges were involved in the SNSE trades by Millennium entities?
Many trades were reported using volume-weighted average price ranges. For example, 10,643 shares were purchased on March 27, 2026, at prices ranging from $25.9197 to $26.88, with similar VWAP ranges disclosed for other purchase and sale blocks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Accepted by SEC EDGAR
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
X
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
MILLENNIUM MANAGEMENT LLC
(Last)(First)(Middle)
399 PARK AVENUE
(Street)
NEW YORK NEW YORK 10022
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Sensei Biotherapeutics, Inc. [ SNSE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
DirectorX10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
03/26/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
XForm filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock03/26/2026P778A$27.2267(1)131,370(2)ISee footnote(3)
Common Stock03/26/2026P1,327A$27.9467(4)131,370(2)ISee footnote(3)
Common Stock03/26/2026P2,601A$28.8539(5)131,370(2)ISee footnote(3)
Common Stock03/26/2026P1,025A$29.9788(6)131,370(2)ISee footnote(3)
Common Stock03/26/2026S583D$26.8797(7)131,370(2)ISee footnote(3)
Common Stock03/26/2026S1,274D$28.6882(8)131,370(2)ISee footnote(3)
Common Stock03/27/2026P10,643A$26.2933(9)142,360(2)ISee footnote(3)
Common Stock03/27/2026P4,384A$27.2826(10)142,360(2)ISee footnote(3)
Common Stock03/27/2026P294A$28.1301(11)142,360(2)ISee footnote(3)
Common Stock03/27/2026S469D$26.7652(12)142,360(2)ISee footnote(3)
Common Stock03/27/2026S36D$27.369(13)142,360(2)ISee footnote(3)
Common Stock03/30/2026P2,992A$25.0784(14)145,678(2)ISee footnote(3)
Common Stock03/30/2026P4,995A$25.99(15)145,678(2)ISee footnote(3)
Common Stock03/30/2026P1,176A$26.7(16)145,678(2)ISee footnote(3)
Common Stock03/30/2026P370A$27.68(17)145,678(2)ISee footnote(3)
Common Stock03/30/2026S518D$25.8501(18)145,678(2)ISee footnote(3)
Common Stock03/30/2026S370D$27.68(19)145,678(2)ISee footnote(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
1. Name and Address of Reporting Person*
MILLENNIUM MANAGEMENT LLC
(Last)(First)(Middle)
399 PARK AVENUE
(Street)
NEW YORK NEW YORK 10022
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
ICS OPPORTUNITIES II LLC
(Last)(First)(Middle)
C/O MILLENNIUM MANAGEMENT LLC
399 PARK AVENUE
(Street)
NEW YORK NEW YORK 10022
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
MILLENNIUM GROUP MANAGEMENT LLC
(Last)(First)(Middle)
399 PARK AVENUE
(Street)
NEW YORK NEW YORK 10022
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
ENGLANDER ISRAEL A
(Last)(First)(Middle)
C/O MILLENNIUM MANAGEMENT LLC
399 PARK AVENUE
(Street)
NEW YORK NEW YORK 10022
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
Explanation of Responses:
1. Represents volume-weighted average price ("VWAP") of purchases of 778 shares of common stock ("Common Stock"), par value $0.0001 per share, of Sensei Biotherapeutics, Inc. (the "Company") on March 26, 2026 at prices ranging from $26.66 to $27.62. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting persons will provide full information regarding the number of shares purchased or sold by the reporting person at each separate price within each range represented by a VWAP disclosed herein.
2. In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2.
3. The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any.
4. Represents VWAP of purchases of 1,327 shares of the Company's Common Stock on March 26, 2026 at prices ranging from $27.70 to $28.4163.
5. Represents VWAP of purchases of 2,601 shares of the Company's Common Stock on March 26, 2026 at prices ranging from $28.7072 to $29.51.
6. Represents VWAP of purchases of 1,025 shares of the Company's Common Stock on March 26, 2026 at prices ranging from $29.79 to $30.105.
7. Represents VWAP of sales of 583 shares of the Company's Common Stock on March 26, 2026 at prices ranging from $26.68 to $27.4650.
8. Represents VWAP of sales of 1,274 shares of the Company's Common Stock on March 26, 2026 at prices ranging from $28.07 to $28.7651.
9. Represents VWAP of purchases of 10,643 shares of the Company's Common Stock on March 27, 2026 at prices ranging from $25.9197 to $26.88.
10. Represents VWAP of purchases of 4,384 shares of the Company's Common Stock on March 27, 2026 at prices ranging from $26.9750 to $27.68.
11. Represents VWAP of purchases of 294 shares of the Company's Common Stock on March 27, 2026 at prices ranging from $28.10 to $28.60.
12. Represents VWAP of sales of 469 shares of the Company's Common Stock on March 27, 2026 at prices ranging from $26.21 to $26.95.
13. Represents VWAP of sales of 36 shares of the Company's Common Stock on March 27, 2026 at prices ranging from $27.2322 to $27.68.
14. Represents VWAP of purchases of 2,992 shares of the Company's Common Stock on March 30, 2026 at prices ranging from $24.495 to $25.1856.
15. Represents VWAP of purchases of 4,995 shares of the Company's Common Stock on March 30, 2026 at prices ranging from $25.50 to $26.48.
16. Represents VWAP of purchases of 1,176 shares of the Company's Common Stock on March 30, 2026 at prices ranging from $26.50 to $26.90.
17. Represents purchases of 370 shares of the Company's Common Stock on March 30, 2026 at $27.68 per share.
18. Represents VWAP of sales of 518 shares of the Company's Common Stock on March 30, 2026 at prices ranging from $25.13 to $26.0734.
19. Represents sales of 370 shares of the Company's Common Stock on March 30, 2026 at $27.68 per share.
Remarks:
Assuming, without conceding, the application of Section 16(b) of the Securities Exchange Act of 1934, the reporting persons have disgorged to the Company all amounts that could be deemed profit realized by them from the transactions in the Company's Common Stock reported on this Form 4 and the other two statements on Form 4 filed by Millennium Management LLC on the same date.
MILLENNIUM MANAGEMENT LLC: By: /s/ Gil Raviv, Global General Counsel05/14/2026
ICS OPPORTUNITIES II LLC, By: Millennium Management LLC, its Investment Manager: By: /s/ Gil Raviv, Global General Counsel05/14/2026
MILLENNIUM GROUP MANAGEMENT LLC: By: /s/ Gil Raviv, Global General Counsel05/14/2026
/s/ Israel A. Englander05/14/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

Keep reading

Trending in the feed

ASML
ASML reports €11.7 billion total net sales and €5.0 billion net income in Q3 2026 Open the live feed